CompletedPhase 3NCT02493335

Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis

Studying NON RARE IN EUROPE: Eosinophilic esophagitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Dr. Falk Pharma GmbH
Principal Investigator
Ralph Mueller, PhD
Dr. Falk Pharma GmbH
Intervention
Budesonide 0.5mg orodispersible tablet twice daily(drug)
Enrollment
204 enrolled
Eligibility
18-75 years · All sexes
Timeline
20162020

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02493335 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Eosinophilic esophagitis

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Eosinophilic esophagitis

← Back to all trials